Comprehensive Age-Stratified Impact of <i>NPM1</i> Mutation in Acute Myeloid Leukemia: A Real-World Experience.

ABSTRACT: Background: While NPM1-mutated AML in the absence of FLT3-ITD generally carries a favorable prognosis, large registry studies suggest the positive prognostic benefit may not extend to patients > 65 years of age. We examined this preferential, age-dependent prognostic impact through a real-world analysis of 2811 adult AML patients. Results: The median overall survival (OS) was significantly better in NPM1^MT compared to NPM1^WT patients [20.86 vs. 17 mo., p = 0.003]. When stratified by age, NPM1^MT patients had higher OS than NPM1^WT patients in the 55-65-year age group (28.62 vs. 16.3 mo., p ≤ 0.0001). This OS benefit was heterogenous and prevailed most strikingly in the 55-60 (68.

SUBMITTER: Dhillon V 

PROVIDER: S-EPMC11940789 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature